TABLE 6.
Activities of antiviral agents against HCV-796-associated resistant replicon variants
| Compound | Replicon | EC50 (μM or pg/ml) ± SD | Resistance (n-fold) |
|---|---|---|---|
| Pegylated IFN-α-2ba | 1b BB7 (WT)b | 22 ± 29 (n = 3) | |
| 796R(1 μM) | 15 ± 13 (n = 7) | 0.7 | |
| Ribavirin | 1b BB7 (WT) | 123 ± 41 (n = 5) | |
| 796R(10 μM) | 29 ± 17 (n = 3) | 0.2 | |
| C316Y | 201 ± 37 (n = 3) | 1.6 | |
| HCV-086 | 1b BB7 (WT) | 0.3 ± 0.1 (n = 4) | |
| 796R(10 μM) | >80 (n = 4) | >40 | |
| C316Y | >80 (n = 2) | >40 | |
| Anthranilate | 1b BB7 (WT) | 0.7 (n = 2) | |
| 796R(10 μM) | 13 ± 1 (n = 3) | >19 | |
| HCV-371 | 1b BB7 (WT) | 12 ± 2 (n = 2) | |
| 796R(10 μM) | 12 ± 5 (n = 3) | 1 | |
| C316Y | 11 ± 1 (n = 2) | 0.8 | |
| 2′-C-methylcytidine | 1b BB7 (WT) | 1.0 (n = 2) | |
| 796R(10 μM) | 0.4 ± 0.1 (n = 4) | 0.4 |
a
IFN, interferon. EC50 is expressed in pg/ml.
b
WT, wild type.